Goodman Financial Corp Increases Holdings in QuidelOrtho Corporation $QDEL

Goodman Financial Corp grew its stake in QuidelOrtho Corporation (NASDAQ:QDEL) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 437,157 shares of the company’s stock after acquiring an additional 48,405 shares during the quarter. Goodman Financial Corp owned 0.64% of QuidelOrtho worth $7,182,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Global Retirement Partners LLC boosted its stake in QuidelOrtho by 3,691.7% in the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after purchasing an additional 886 shares in the last quarter. Camelot Portfolios LLC bought a new stake in QuidelOrtho during the 4th quarter valued at about $29,000. Hantz Financial Services Inc. increased its stake in QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after purchasing an additional 362 shares in the last quarter. Larson Financial Group LLC raised its holdings in QuidelOrtho by 322.2% in the third quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock worth $39,000 after buying an additional 1,015 shares during the last quarter. Finally, Leonteq Securities AG raised its holdings in QuidelOrtho by 555.2% in the first quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock worth $57,000 after buying an additional 2,937 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on QDEL shares. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. UBS Group restated a “neutral” rating and issued a $12.00 price objective on shares of QuidelOrtho in a report on Thursday, May 7th. Citigroup upped their price objective on QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. increased their target price on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $13.62.

QuidelOrtho Trading Up 0.1%

Shares of QDEL stock opened at $18.24 on Friday. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. QuidelOrtho Corporation has a 12-month low of $9.92 and a 12-month high of $35.58. The stock has a market capitalization of $1.24 billion, a P/E ratio of -1.02 and a beta of 0.69. The firm’s 50 day moving average is $14.17 and its 200 day moving average is $19.17.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The company had revenue of $619.80 million for the quarter, compared to analysts’ expectations of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. QuidelOrtho’s quarterly revenue was down 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Research analysts expect that QuidelOrtho Corporation will post 1.87 earnings per share for the current year.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.